Connect Biopharma
Connect Biopharma's revenue fell 99.8% to $0 million in fiscal 2025. Its operating margin was −90,740.6%, down from −86.2% a year earlier. Free cash flow was −$52 million. The diluted share count rose 0.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Connect Biopharma does
Connect Biopharma is a clinical-stage biopharmaceutical company based in San Diego, California. Clinical-stage means its drug candidate is still being tested in people and is not approved for sale. It is working on treatments for asthma and chronic obstructive pulmonary disease (COPD), two long-term lung diseases that make it hard to breathe.
Its drug candidate is rademikibart, an antibody designed to block interleukin-4-receptor alpha (IL-4Rα), a protein involved in inflammation. The company is focused on acute asthma, where it says about 50% of patients fail to improve on first-line treatments, and on COPD. It believes that, if approved, rademikibart could offer a way to treat patients during flare-ups and might reduce hospital stays and repeat emergency visits.
The company has no approved products and no product sales. It relies on raising money from investors, and it runs some clinical trials.
Its biggest risks, as it describes them
- It has a short operating history, significant losses, and expects more losses.
- Raising more capital may dilute shareholders or limit what the company can do.
- Clinical development is lengthy and costly, and the outcome is uncertain.
- Trouble enrolling patients could delay its trials.
- Serious side effects, or regulators not accepting data from trials at international sites, could delay or stop development.
Income statement
Connect Biopharma lost money in fiscal 2025: a net loss of $56 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 268 | 79 | 118 | 94 | 44 |
| Debt incl. finance leases | — | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | — | −79 | −118 | −94 | −44 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −5,450.4x | −5,681.7x | −3,002.4x | — | — |
| Current ratio | 15.3x | 10.0x | 4.8x | 11.5x | 3.7x |
| Quick ratio | 15.3x | 10.0x | 4.8x | 11.5x | 3.7x |
Cash flow
Projections
Project Connect Biopharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $4.4 million of Connect Biopharma shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 29, 2026 | James HuangDirector | Bought | 150,000 | $2.48 | $372,000 | Form 4 |
| Mar 31, 2026 | James HuangDirector | Bought | 1,160,000 | $3.45 | $4.0 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 3 of 8 | 1 of 8 |
| Rule of 40 | — | — | −80,787.2% |
| Altman Z'' | −2.97 | 3.74 | −22.77 |
| Accruals ratio | −9.5% | 7.0% | −5.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | Pass | Fail |
| F-score | — | 3 of 8 | 1 of 8 |
Compare
Put Connect Biopharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Connect Biopharma | FY25 | −99.8% | −90,740.6% | −80,687.5% | — | — | 1 | |
| aTYR Pharma | FY25 | −19.1% | −40,856.3% | −32,664.7% | — | — | — | Compare |
| BioRestorative Therapies | FY25 | −10.3% | −4,350.1% | −3,031.7% | — | — | — | Compare |
| Cardiff Oncology | FY25 | −13.2% | −8,256.3% | −6,402.5% | — | — | 2 | Compare |
| PMGC Holdings | FY25 | — | — | −1,080.5% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | — | — | 0 | 26 | 0 |
| Revenue growth | — | — | — | — | — | — | −99.8% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | — | — | 80 | 97 | 53 | 29 | 38 |
| Operating income | — | — | −98 | −119 | −69 | −22 | −58 |
| Net income | — | — | −202 | −118 | −62 | −16 | −56 |
| Diluted EPS (US$) | — | — | −3.88 | −2.15 | −1.13 | −0.28 | −1.00 |
| Diluted shares (millions) | 17 | 17 | 52 | 55 | 55 | 55 | 56 |
| Cash flow | |||||||
| Cash from operations | — | — | −84 | −102 | −48 | −24 | −51 |
| Capital expenditure | — | — | 4 | 4 | 0 | 1 | 0 |
| Free cash flow | — | — | −88 | −106 | −48 | −24 | −52 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | — | 9 | 7 | 5 | 7 | 4 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | — | 155 | 268 | 79 | 118 | 94 | 44 |
| Debt incl. finance leases | — | — | — | 0 | 0 | 0 | 0 |
| Total assets | — | — | 291 | 174 | 127 | 101 | 56 |
| Total liabilities | — | — | 19 | 16 | 26 | 9 | 14 |
| Shareholders' equity | — | −157 | 272 | 158 | 102 | 92 | 42 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | −86.2% | −90,740.6% |
| Net margin | — | — | — | — | — | −60.0% | −86,687.5% |
| Free cash flow margin | — | — | — | — | — | −93.6% | −80,687.5% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | −80,787.2% |
| Return on capital | — | — | — | — | −178.2% | — | — |
| Return on equity | — | — | — | −54.8% | −47.8% | −16.1% | −82.7% |
| Return on assets | — | — | — | −50.8% | −41.2% | −13.7% | −70.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — |